Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

How will Meta's nuclear deal impact AI energy use? Why did Nvidia regain title as top valued company? What effect will Trump's steel and aluminum tariffs have? How is South Korea's new president shaping trade policy? Why are auto makers concerned about China's mineral export curbs? What caused CrowdStrike's revenue forecast to weaken? How are US job openings rising amid trade tensions?

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

novartis.com/news/media-releases/novartis-pluvictotm-demonstrates-statistically-significant-and-clinically-meaningful-rpfs-benefit-patients-psma-positive-metastatic-hormone-sensitive-prostate-cancer

Ad hoc announcement pursuant to Art. 53 LR
- At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival…

This story appeared on novartis.com, 2025-06-02 15:00:49.570000.